Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30600995 | 0.96 | SLC15A2 (0.39) | SLC15A2FURIN | |
| SCHEMBL29530561 | 0.94 | SLC15A2 (0.39) | SLC15A2CRHR1CRHR2 | |
| SCHEMBL29381521 | 0.94 | BACE1 (0.40) | SLC15A2CRHR1CRHR2 | |
| SCHEMBL29833166 | 0.93 | CALCR (0.38) | SLC15A2 | |
| SCHEMBL4200033 | 0.93 | CALCR (0.39) | SLC15A2ITGB3ITGAVCRHR1CRHR2 | |
| SCHEMBL4200040 | 0.93 | CALCR (0.39) | SLC15A2ITGB3ITGAVCRHR1CRHR2 | |
| SCHEMBL29530841 | 0.92 | SLC15A2 (0.39) | SLC15A2ITGB3ITGAVFURIN | |
| SCHEMBL29732685 | 0.91 | SLC15A2 (0.44) | SLC15A2FURIN | |
| SCHEMBL31320779 | 0.90 | CALCR (0.40) | ITGB3ITGAVCRHR1CRHR2 | |
| SCHEMBL30441425 | 0.90 | SLC15A2 (0.43) | SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333488-A1 | PEPTIDE-HINGE-FREE FLEXIBLE ANTIBODY-LIKE MOLECULE | BIOMOLECULAR HOLDINGS LLC (US) | 2025-10-30 | — | — | US | claimed |
| EP-4257193-A2 | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS | Sanofi (FR) | 2023-10-11 | — | — | EP | claimed |
| EP-3443006-B1 | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS | SANOFI SA (FR) | 2023-08-02 | — | — | EP | claimed |
| CN-109311966-B | Trispecific and/or trivalent binding proteins for use in the prevention or treatment of HIV infection | 赛诺菲 | 2023-03-10 | — | — | CN | claimed |
| EP-4705355-A1 | MOLECULES MODULATING WNT SIGNALING PATHWAYS AND USES THEREOF | Surrozen Operating, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250333488-A1 | PEPTIDE-HINGE-FREE FLEXIBLE ANTIBODY-LIKE MOLECULE | BIOMOLECULAR HOLDINGS LLC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250312475-A1 | BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION | SANOFI (FR) | 2025-10-09 | — | — | US | disclosed |
| US-12371480-B2 | Peptide-hinge-free flexible antibody-like molecule | BIOMOLECULAR HOLDINGS LLC (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4536676-A2 | METHODS FOR PURIFICATION OF MULTI-SPECIFIC ANTIBODIES | Sanofi (FR) | 2025-04-16 | — | — | EP | disclosed |
| CN-119343359-A | Method for purifying multispecific antibodies | 赛诺菲 | 2025-01-21 | — | — | CN | disclosed |
| CN-119291194-A | Method for quantifying a polypeptide | 建新公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2024227103-A1 | MOLECULES MODULATING WNT SIGNALING PATHWAYS AND USES THEREOF | Surrozen Operating, Inc. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-11739160-B2 | PseudoFab-based multispecific binding proteins | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| EP-3443006-B1 | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS | SANOFI SA (FR) | 2023-08-02 | — | — | EP | disclosed |
| CN-109311966-B | Trispecific and/or trivalent binding proteins for use in the prevention or treatment of HIV infection | 赛诺菲 | 2023-03-10 | — | — | CN | disclosed |
| US-20220403012-A1 | PEPTIDE-HINGE-FREE FLEXIBLE ANTIBODY-LIKE MOLECULE | BIOMOLECULAR HOLDINGS LLC (US) | 2022-12-22 | — | — | US | disclosed |
| CN-114885609-A | pseudo-Fab based multispecific binding proteins | 赛诺菲 | 2022-08-09 | — | — | CN | disclosed |
| US-20220226495-A1 | BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION | SANOFI (FR) | 2022-07-21 | — | — | US | disclosed |
| US-11345745-B2 | Peptide-hinge-free flexible antibody-like molecule | BIOMOLECULAR HOLDINGS LLC (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220119553-A1 | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS | SANOFI (FR) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312475-A1 | BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION | CD4, HAVCR2, TIMCC | SLC15A2 2447/4885ITGB3 508/4885ITGAV 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.